Trial · NCT06889649
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649, Phase 2, Recruiting, Peking University First Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC. Trials, record NCT06889649. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06889649
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
- NCT number
- NCT06889649
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Peking University First Hospital
- Conditions
- Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
- Interventions
- Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI)
- First posted
- 2025-03-21
- Last updated
- 2025-03-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival 1 (PFS1) | From the start of SABR treatment to the first disease progression, up to 2 years. This primary endpoint assesses how long patients survive without disease progression while receiving the combination therapy. | PFS1 is defined as the time from the initiation of stereotactic ablative body radiotherapy (SABR) to the first occurrence of disease progression, as determined by radiological imaging (CT, MRI, or PET/CT) based on RECIST criteria. Disease progression is defined as an increase in the size of target lesions or the appearance of new lesions. |
| Secondary | Overall Survival (OS) | From the start of treatment to death or until the end of the study (up to 3 years). This secondary endpoint will help evaluate the overall survival benefits of the combined treatment over a longer period. | Overall survival is defined as the time from the start of treatment (SABR combined with Axitinib and Toripalimab) to death from any cause. |
| Secondary | Progression-Free Survival 2 (PFS2) | From the start of SABR treatment to the initiation of next-line treatment or death (an average of 3 year) | PFS2 is defined as the time from the start of stereotactic ablative body radiotherapy (SABR) to the need for second-line treatment due to disease progression or clinical deterioration, or to death. This will be measured by assessing the time until the initiation of a next-line treatment regimen or the occurrence of death. |
| Other | Local Control (LC) | Through study completion, an average of 3 year | Local Control is defined as the percentage of patients who have no evidence of disease progression in the irradiated lesions after treatment |
| Other | Objective Response Rate (ORR) | From the start of treatment to the first radiological evaluation to the best response(an average of 6 months) | Objective Response Rate is defined as the percentage of patients who achieve a complete response (CR) or partial response (PR) |
| Other | Disease Control Rate (DCR) | From the start of treatment to the first disease progression, up to 2 years. | Disease Control Rate is defined as the percentage of patients who achieve a complete response (CR), partial response (PR), or stable disease (SD) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40503038 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06889649
GET https://conductscience.org/api/trials/v1/NCT06889649/registered